Clinical Trials
99 trialsNCT03213678 2026-04-21
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03213665 2026-04-13
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03526250 2026-04-03
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT02945800 2026-04-02
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT05046314 2026-03-19
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2 Completed
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT05071001 2026-02-05
OSE
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Completed
NCT02415816 2026-02-04
Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas
St. Jude Children's Research Hospital
Phase NA Completed
NCT01858168 2025-12-19
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma
Massachusetts General Hospital
Phase 1 Completed
NCT04067115 2025-12-17
U01CA236220
Sarcoma Alliance for Research through Collaboration
Phase 1/2 Completed
NCT02162732 2025-11-03
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
Phase NA Completed
NCT07215728 2025-10-10
AMLAS
University of Milano Bicocca
Completed
NCT05275426 2025-08-15
A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT06659224 2025-07-23
The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma
Suez Canal University
Completed
NCT00898755 2025-05-02
Collecting and Storing Tissue From Young Patients With Cancer
Children's Oncology Group
Completed
NCT05772312 2025-03-26
Onco-QoL
Istituto Ortopedico Rizzoli
Completed
NCT00638898 2025-03-20
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
City of Hope Medical Center
Phase 1 Completed
NCT06851221 2025-02-28
Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma
Meyer Children's Hospital IRCCS
Phase NA Completed
NCT03190174 2025-02-17
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Sarcoma Oncology Research Center, LLC
Phase 1/2 Completed
NCT01586104 2025-02-10
Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases
Ann & Robert H Lurie Children's Hospital of Chicago
Phase NA Completed
NCT03220035 2025-01-27
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT02076906 2025-01-01
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
Children's National Research Institute
Phase 1 Completed
NCT05302921 2025-01-01
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
Phase 2 Completed
NCT03507491 2024-10-04
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
Phase 1 Completed
NCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT05093322 2024-06-07
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
NCT01661400 2024-01-31
ASCR
Washington University School of Medicine
Phase 1 Completed
NCT06202599 2024-01-17
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
Peking University People's Hospital
Completed
NCT01336803 2023-12-27
Osteosarcoma
Stanford University
Phase 2 Completed
NCT02736565 2023-11-13
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
Gradalis, Inc.
Phase 1 Completed
NCT02644460 2023-10-26
AflacST1501
Emory University
Phase 1 Completed
NCT04854018 2023-08-14
Indo-cyanine Green (ICG) in Paediatric Oncology MIS
Birmingham Women's and Children's NHS Foundation Trust
Phase 4 Completed
NCT05100368 2023-07-20
The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma
Istituto Ortopedico Rizzoli
Completed
NCT03542097 2023-05-15
MGMTLiberati
Istituto Ortopedico Rizzoli
Completed
NCT02890758 2023-02-21
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Case Comprehensive Cancer Center
Phase 1 Completed
NCT04661852 2023-02-15
Cabozantinib With Topotecan-Cyclophosphamide
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04956198 2023-02-14
Drug Sensitivity and Mutation Profiling
Florida International University
Completed
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT03441360 2022-10-05
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Eisai Inc.
Phase 2 Completed
NCT02063022 2022-09-19
EW-1
Italian Sarcoma Group
Phase 3 Completed
NCT02727387 2022-09-19
EW-2
Italian Sarcoma Group
Phase 2 Completed
NCT03245450 2022-06-28
Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT03275818 2022-06-07
ABRADES
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT01061840 2022-03-15
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Gradalis, Inc.
Phase 1 Completed
NCT02982941 2022-02-08
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
MacroGenics
Phase 1 Completed
NCT04512495 2021-12-10
SAMHY SARCOME
Institut Claudius Regaud
Phase NA Completed
NCT01222767 2021-10-29
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
PharmaMar
Phase 2 Completed
NCT01210209 2021-05-19
GENEWING
Institut Curie
Completed